Expert Interviews

Acoustic variables, like shimmer and jitter, that are typically undetectable in human speech can be detected with tablet technology and serve as biomarkers for mental acuity.

Amesh Adalja, MD, explains how physicians can rebut social media vaccine claims with concise, referenced facts and patient-centered communication.

Bonnet says a clear understanding of a patient's weight and emotional history are critical to ensure optimal use of GLP-1 therapy in a successful weight management program.

Amesh Adalja, MD, infectious disease physician, outlines effective communication strategies that respect patient concerns while reinforcing physician credibility.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

An expert discusses how the stage and diverse presentations of atopic dermatitis, especially in underserved and darker-skinned patients, influence treatment decisions, highlighting the promise of new nonsteroidal therapies and the importance of personalized, patient-centered care to improve quality of life.

An expert discusses the vital role of patient education, coordinated care, and timely dermatology referrals in managing atopic dermatitis, emphasizing holistic support and the use of systemic therapies for severe or treatment-resistant cases to improve long-term outcomes.

An expert discusses the importance of careful topical steroid use to minimize adverse effects in atopic dermatitis, while highlighting newer, more potent nonsteroidal treatments such as PDE4 and JAK inhibitors as promising safer alternatives for effective long-term disease control.

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse effects and withdrawal, while emphasizing emerging nonsteroidal therapies as promising safer alternatives for personalized care.

An expert discusses the shift from reactive to proactive treatment of atopic dermatitis (AD), emphasizing personalized care and the growing role of advanced nonsteroidal topicals—such as PDE4 and JAK inhibitors—alongside updated guidelines aimed at improving clinician awareness and patient outcomes.